Janux Therapeutics (JANX) Cash from Operations (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Cash from Operations of 12337000.0 for Q1 2026, up 27.53% year-over-year from 9673671.78 in Q1 2025, and up 56.78% quarter-over-quarter from 28542000.0 in Q4 2025.
Janux Therapeutics (JANX) Cash from Operations (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Cash from Operations for 7 consecutive years, with 12337000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 27.53% year-over-year to 12337000.0; the TTM figure through Mar 2026 stood at 77548000.0 (down 68.58% YoY), while the FY2025 annual figure was 82235000.0, down 87.69% from the prior year.
- Cash from Operations climbed to 12337000.0 in Q1 2026 per JANX's latest filing, from 28542000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 2231000.0 in Q3 2024 and bottomed at 28542000.0 in Q4 2025.
- Historically, Cash from Operations has averaged 13640176.47 across 5 years, with a median of 12856000.0 in 2025.
- Annual changes were most pronounced in 2024 — Cash from Operations surged 80.95% — and 2025, when it plunged 476.24%.
- Janux Therapeutics' Cash from Operations stood at 11913000.0 in 2022, then increased by 16.89% to 9901000.0 in 2023, then plunged by 68.92% to 16725000.0 in 2024, then plunged by 70.65% to 28542000.0 in 2025, then soared by 56.78% to 12337000.0 in 2026.
- Business Quant data shows JANX's Cash from Operations at 12337000.0 in Q1 2026, 28542000.0 in Q4 2025, and 12856000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - | 12.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.48 Mn |
| Jun 30, 2026 | 12.48 Mn |
| Mar 31, 2026 | -12.34 Mn |
| Mar 31, 2026 | -12.34 Mn |
| Dec 31, 2025 | -28.54 Mn |
| Dec 31, 2025 | -28.54 Mn |
| Sep 30, 2025 | -12.86 Mn |
| Sep 30, 2025 | -12.86 Mn |
| Jun 30, 2025 | -23.81 Mn |
| Jun 30, 2025 | -23.81 Mn |
| Mar 31, 2025 | -17.02 Mn |
| Mar 31, 2025 | -17.02 Mn |
| Dec 31, 2024 | -16.73 Mn |
| Dec 31, 2024 | -16.73 Mn |
| Sep 30, 2024 | -2.23 Mn |
| Sep 30, 2024 | -2.23 Mn |
| Jun 30, 2024 | -10.02 Mn |
| Jun 30, 2024 | -10.02 Mn |
| Mar 31, 2024 | -14.84 Mn |
| Mar 31, 2024 | -14.84 Mn |